Tumor Models

WuXi Biology has a significant experience in oncology drug discovery. We offer a large collection and tumors model for small & large molecule drug discovery.

  • A large collection of cell line-derived xenograft (CDX) tumor models with an imaging based orthotopic/metastatic CDX platform covering 16 tumor types
  • Patient-derived xenograft (PDX) tumor models covering 20 cancer types, drug resistant model and mouse clinical trial enabling translational research
  • Syngeneic tumor models covering 20 cancer types, enabled with immunotherapy SOC, TIL analysis and RNAseq profiling.
  • Human immune checkpoint gene KI mouse models
  • hPBMC/HSC humanized models

Cell line-derived xenograft (CDX) tumor models

  • 280+ validated models covering full range of cancer types
  • 77+ cell lines derived from PDX models
  • Available data of sensitivities to SOC (standard of care)
  • Imaging-based orthotopic/metastatic tumor models
  • Brain/bone metastatic models of lung/breast cancer cell lines

Tumor Types

Cell lines

Bladder

T24/83, RT112/84, UM-UC-3, J82

Brain

U87*, LN-229*

Breast

Cal51*, BT-474*, HCC1954*, MDA-MB-231*, MDA-MB-468*, HCC1806*, MCF7*, HCC1937, MDA-MB-436*, SUM-52Pe, JIMT-1*, MDA-MB-361*, HCC-70, SUM 159PT, MFM-223, T47D*, HCC1428, Z-75-1*

Cervical

SW756

Colorectal

Colo205*, HT29, HCT-116*, HCT-15*, LS180*, LS174T*, SW620*, HT55*, DLD-1, Lovo, COLO-320DM, RKO, Caco-2, T84, WiDr, SW480, SW 48, LS411N, COLO 201

Duodenal

HuTu80

Esophageal

T.Tn, OE21*

Gastric

NUGC4*, SNU-1, SNU-16*, MCG-803, NCI-N87*, SNU-5, MKN45*, HS 746T

Head & Neck

Cal 27, RPMI2650, SCC-9, Fadu*

Leukemia

HEL 92.1.7*, MV4-11*, CCRF-CEM, HL-60, K562, KG-1, MOLT-4, Kasumi-1*, Nalm-6*, THP-1, SET-2, PL-21, MLK-1

Lymphoma

Daudi*, SU-DHL-2*, SU-DHL-10, Granta-519, Maver-1, Mino, NAMALWA, Raji, Ramos, RL, WSU-DLCL2, Z-138, U379, DoHH2, Farage*, Pfeiffer, REC-1*, OCI-LY10, TMD-8*

Tumor Types

Cell lines

Liver

BEL-7404*, Hep3B*, Huh 7*, HepG2, SNU-182, QGY-7703, SNU-398, JHH-7*, MHCC97H*

Lung

NCHI-H1650, NCI-H226, NCI-H460, PC9*, A549*, Calu-1, Calu-6*, EBC-1, A427, NCI-H647, MSTO-211H, NCI-H292, NCI-H322, NCI-H358*, NCI-H441, NCI-H520, NCI-H1957*, NCI-H2228, SK-MES-1, NCI-H1229, HCC-827*, HCC400646, NCI-H1703, NCI-H727, NCI-H2122*, DV-90, NCI-H69*, NCI-H1417*, NCI-H446, NCI-H526*, NCI-H82, SHP-77, Calu-3, NCI-H2170

Melanoma

A375*, SK-MEL-24, SK-MEL-28, COLO 829*, SK-MEL-5, MDA-MD-435S

Myeloma

KMS-28BM, KMS-11, MOLP-8*, NCI-H929, RPMI 8226*, MM.1S*

Neuroblastoma

CHP-134*, SK-N-AS*, BE(2)-C*, SH-SY5Y

Ovary

A2780*, SK-OV-3*, ES-2*, OVCAR-3, TOV21G

Pancreas

BxPC3*, Mia-pa-ca-2*, KP4, PANC-1*, CAPAN-1, Panc 02.13*

Prostate

PC-3*, DU145, LNCap*, VCaP, 22RV.1


Renal

786-O* ACHN, Caki-1, SK-NEP-1, A498

Sarcoma

HT1080, A673, KHOS/NP, 143B, SJSA-1*, SAOS-2, A204, G401

Skin

A431*

*: validated with SOC compound

28 Luciferase Labelled Orthotopic/Metastatic Tumor Models

  • Cover 16 tumor types
  • Bioluminescent imaging system in SPF barrier
O: orthotopic model  M: metastatic mode  S: validated with SOC

Patient-derived xenograft (PDX) tumor models

  • 1380+ PDX models covering full range of cancer types
  • Fully-characterized models with genetic, molecular and pharmacological profiling
  • Drug-resistant PDX models available
  • in vitro screening and derivative PDXC/PDXO models
  • IO-PDX panel with hPBMC humanization

A Comprehensive PDX Collection of Asia Prevalent Tumors

Clinical Diagnosis

Profiled

Established

Lung cancer

NSCLC

Adeno

34

38

SCC

108

117

Large Cell

3

3

SCLC

4

4

Others

20

34

Gastric cancer

77

93

HCC

139

284

Colorectal cancer

102

105

Esophageal cancer

63

90

Cholangiocarcinoma

36

41

Cervical cancer

2

4

Clinical Diagnosis

Profiled

Established

Pancreatic cancer

54

57

Kidney cancer

8

9

Head & Neck cancer

14

27

Breast cancer

16

17

Melanoma

11

14

Liposarcoma

3

10

GIST

7

13

Nasopharyngeal carcinoma

2

4

Ovarian cancer

1

2

Gallbladder cancer

7

9

Glioma

4

4

Lymphoma

19

20

Endometrial cancer

4

4

Sarcoma

1

2


Syngeneic tumor models

  • 70 Syngeneic models (mouse, rat, hamster)
  • Responsiveness to immune checkpoint inhibitors (PD-1, PD-L1, CTLA-4, etc.)
  • Tumor-infiltrating leukocytes (TILs) map
  • WES, RNA-seq and scRNA-seq characterization
Note: 16 models with reference compound treatment data were marked as S, 17 models with genomic profiling data were marked with GP, 12 models with baseline TIL data were marked as T


Genetically engineered models

  • 48 engineered cell lines based on construct overexpression or gene knock-in
  • Pharmacologically validated in vitro and in vivo
  • Focusing at drug-resistant mutation introduction and IO-related checkpoint humanization
  • Example targets: EGFR, ROS1, ALK, RET, FLT3, BTK, Claudin18.2, PD-L1, etc.

hPBMC/HSC Humanized Models

hPBMC Humanized Models

  • Established models for immune-checkpoint inhibitor and bi-specific antibody candidates in a human-resembling immune system.
  • Annotation for both immune cells (phenotyping, biomarker, functions) and tumor cells (expression, mutation etc.)
  • Different PBMC delivery systems (systemic injection or co-inoculation with tumor)

HSC Humanized Models

  • Available humanized models from CIEA, combine with WuXi PDX/CDX models.
  • Customizable with human cytokine transgenic mice (GM-CSF/hIL-3 or hIL-2) to improve the reconstitution of myeloid lineage.

A List of Established hPBMC Humanized Models

Cancer Type

Established

Ongoing/in plan

Lung Cancer

HCC827, **NCI-H1975

A549

CRC

LOVO, HT29, HTC-116

Colo-205

Lymphoma

**Raji, Ramos

Liver cancer

Hep3B

Melanoma

*A375

Huh7

Breast Cancer

MDA-MB-231

A2058

Skin Cancer

**A431

Multiple Myeloma

U266B1

Renal Cancer

KI-12-0060

Ovarian Cancer

SK-OV-3

Gastric Cancer

SNU-16

NCI-N87

Sarcoma

HT-1080

Bold: has been applied for efficacy study     |     *Popular models


Human immune checkpoint gene KI mouse models

KI (Knock-in) mice offer the possibility to study clinical grade checkpoint antibodies targeting human checkpoints in the context of a fully functional immune system. WuXi Biology offers efficacy studies in different mouse strains with human targets KI in mice and cell line, and comprehensive flow cytometry to evaluate target expression and immune function.

  • Collection of various targets and background mouse strains
  • Validated with launched or most advanced clinical grade checkpoint antibodies
  • Double checkpoint KI mice customizable for combination (PD1 + OX40, PD1 + TIM3 etc.)

Availability

Model / Strain

Ready to use

• hPD-1 C57BL/6
• hPD-1 BALC/c
• hCTLA-4 C57BL/6
• hOX40 C57BL/6
• hTIM-3 C5BL/6

Customizable

• hCTLA- BALB/c
• hCD137 C57BL/6
• hLAG3 C57BL/6
• hLAG3 BALB/c
• hVISTA C57BL/6
• hTIGIT C57BL/6
• hTIM-3 BALB/c
• And Double Knock-ins


Immuno-avatar humanized models

  • Mouse models harboring human tumor and human immune ceils
  • Three different diagram of hPBMC humanization for mature T cell engraftment
  • HSC (CD34+) avatar and next generation immune avatar for multiple-lineage engraftment (Myeloid, NK, DC etc.)
  • IO-CDX and IO-PDX models with cancer targets and HLA information

Drug-resistant models

  • Engineered cell line derived xenograft models
  • Acquired drug-resistant CDX and PDX models
  • Intrinsic drug-resistant PDX models